ASM

Leuven, Belgium
Leuven, Belgium
SEARCH FILTERS
Time filter
Source Type

-- TGV-inhalonix, a New York drug development company behind  ground-breaking Mul-1867 which gives hope to treating life-threatening, antibiotic-resistant bacterial lung infections in patients suffering from cystic fibrosis, announced that Mul-1867 has shown tremendous potential against clinical isolates of fungi from patients with cystic fibrosis and other severe lung infections.The findings were published in Europe's leading discovery journal -  International Journal of Antimicrobial Agents - and will be presented at the upcoming ASM - 2017 conference in June.The article written by Victor and George Tetz, the scientific core at TGV-inhalonix, details the results of a collaborative study along with VA Medical Center and University of Massachusetts for antifungal activity of Mul-1867.  The authors report that they revealed high activity of Mul-1867 against multidrug-resistant strains ofspp andspp, which are especially risky for people with cystic fibrosis and patients with compromised immune system including those with lung transplans.  "Fungal infections represent a crucial and unsolved problem for patients with cystic fibrosis, playing a dramatic role in their morbidity," as stated by the  researchers."We have already confirmed a broad spectrum activity of Mul-1867 against multiresistant bacterial isolates such asandalong with early, compassionate use human clinical data. Its high anti-infective efficacy could make it a breakthrough new agent for addressing a variety of lung infections starting with those in Cystic Fibrosis patients," said Dr. George Tetz.For a few decades, the problem of antibiotic resistant fungal infections posed treatment challenges in patients suffering from a variety of pathologies and finding a solution is crucial for cystic fibrosis patients.  "Our studies indicate that Mul-1687 also holds promise as a treatment against numerous other lung indications with fungal etiology, including HIV, blood malignancies and can help patients undergoing lung transplantations.  We believe our research has unlocked a key for slowing the growth of these potentially fatal antibiotic-resistant pathogens," said Dr. Victor Tetz."The recent increase in the incidence of life-threatening infections caused by resistant fungi, including Candida and Aspergillus, is particularly concerning, because currently available antifungal agents may no longer be effective," said Dr. Haran T Schlamm of HTS Pharma Consulting, LLC, an advisor to TGV-Inhalonix.TGV-inhalonix has recently obtained an Orphan Drug status for Mul-1867, which will provide incentives to develop drugs for treating rare diseases.


News Article | May 12, 2017
Site: www.eurekalert.org

Washington, DC - May 12, 2017 - A team of researchers from the United Kingdom has developed a novel method for assessing human/pathogen interactions in the natural environment, using citizen scientists wearing boot socks over their shoes during walks in the countryside. In the process, they found that slightly less than half of the socks were positive for the gastrointestinal pathogen, Campylobacter. The research is published in Applied and Environmental Microbiology, a journal of the American Society for Microbiology. In the study, groups of volunteer walkers wearing boot socks on one foot took regular four kilometer (two and a half mile) walks on each of six pathways in the countryside, over a 16 month period. The pathways are located in two regions of the UK, the livestock-dominated North West, and East Anglia, much of which is devoted to cropland, said coauthor Natalia Jones, PhD, Senior Research Associate, University of East Anglia. Following the walks, the walkers mailed the socks to the lab, where coauthors used microbial culture and PCR methods to determine the presence, and species of Campylobacter. As measured on boot socks, Campylobacter was more prevalent in livestock-dominated North West than in East Anglia (55.8% of socks, vs 38.6%). Campylobacter peaked during winter in both regions, and peaked again in spring in North West. Precipitation was associated with greater Campylobacter, and higher temperatures with less. The results "are consistent with our understanding of Campylobacter survival and the probability of material adhering to boot socks," according to the report. C. jejuni was the most commonly found species, with C. coli largely restricted to the livestock dominated North West, according to the report. Source attribution analysis suggested that the major source of C. jejuni was sheep in North West, and wild birds in East Anglia. The motivation for the study was the desire to develop an efficient sampling method to explore the potential for transfer of Campylobacter from the environment to humans through visits to the countryside, and to determine whether any such risk varied seasonally, said Jones. Campylobacter is the most common bacterial cause of diarrheal disease in the developed world. "It is known that food is often a source of Campylobacter infections in humans, but we also know that exposure through food cannot explain all the cases seen in the human population," said Jones. "Exploring other potential routes was a key motivation." Conventional sampling is based on sampling from a single point, called spot sampling, and does not sample human-pathogen interactions. "Ultimately, this research could lead to interventions to reduce the risk to humans," said Jones. The American Society for Microbiology is the largest single life science society, composed of over 50,000 scientists and health professionals. ASM's mission is to promote and advance the microbial sciences. ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.


Welding rod for performing a plastic weld on plastic panels, so as to fasten them to one another, and related methods. Use of welding rods, or structural and welding profiles, having at least one tongue below which is a boss extending longitudinally and forming a material reserve. Once the welding rod is placed along a desired weld line, under the effect of heating, the material reserve is softened and fuses with a panel portion situated opposite it, so as to produce a final plastic weld, and the tongue is folded down on said weld line, to conceal it.


BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at ASM Microbe 2017, to be held June 1 – 5 in New Orleans. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry. “As we advance our clinical program, we continue to be encouraged by the study outcomes that add to our breadth of knowledge about the safety and efficacy of once-daily oral and IV omadacycline in the treatment of bacterial infections,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer, Paratek. “Results from the 10 studies being presented at ASM Microbe include new phase 1 data examining omadacycline in patients with uncomplicated urinary tract infection as well as additional analyses of microbiology date that help further our understanding of how omadacycline may be used in a clinical setting. We continue to be excited about the potential for this compound to treat severe bacterial infections, particularly when resistance is of concern.” Paratek Presentations on Friday, June 2, 2017 at 12:45 p.m. – 2:45 p.m. CDT (1:45 p.m. – 3:45 p.m. EDT) Poster Session 45: Infection Prevention and Control: Skin, Soft Tissue and Bone Infections Paratek Presentations on Saturday, June 3, 2017 at 12:15 p.m. – 2:15 p.m. CDT (1:15 p.m. – 3:15 p.m. EDT) Poster Session 185: Antibacterial Resistance: In vitro Activity and Resistance to Tigecyline, Fosfomycin and Derivatives Paratek Presentations Sunday, June 4, 2017 at 12:15 p.m. – 2:15 p.m. CDT (1:15 p.m. – 3:15 p.m. EDT) Poster Session 341: Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents Poster Session 345: Clostridium difficile: Epidemiology and Strategies for Prevention and Treatment of CD Infections About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, when approved, will be the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is a new, once-daily oral and intravenous broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for the target indications. In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin structure infections (ABSSSI) demonstrating the efficacy and general safety and tolerability of intravenous (IV) to once-daily oral omadacycline compared to linezolid. In April 2017, Paratek announced positive efficacy data in a Phase 3 registration study in community-acquired bacterial pneumonia (CABP) demonstrating the efficacy and general safety and tolerability of IV to once-daily oral omadacycline compared to moxifloxacin. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. This study completed enrollment in May 2017 and top-line data are expected in mid-July. The Company plans to submit its new drug application (NDA) in the U.S. as early as the first quarter of 2018 with an EMA submission later in 2018. In addition to its Phase 3 program for omadacycline, a Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016 and positive top-line PK proof-of-principle data was reported in November 2016. The Company plans to begin enrolling patients in a proof-of-concept Phase 2 study of omadacycline in acute pyelonephritis, the most common subset of complicated urinary tract infections, as early as December 2017. In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore the utility of omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance including plague and anthrax. In April 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the Company, and Zai Lab (Shanghai) Co., Ltd., entered into a License and Collaboration Agreement. Under the terms of the Agreement, the Company granted Zai an exclusive license to develop, manufacture, and commercialize omadacycline in the People’s Republic of China, Hong Kong, Macau and Taiwan, for all human therapeutic and preventative uses, other than biodefense. Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan and Paratek reported positive results from two identical Phase 3 registration studies of sarecycline for the treatment of moderate to severe acne vulgaris in March 2017. Allergan has publicly announced plans to submit an NDA in the U.S. in the second half of 2017. Forward Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical studies, prospects, potential and expected results, including statements about the timing of advancing omadacycline and otherwise preparing for clinical studies, the timing of enrollment in our clinical studies and our reporting of the results of such studies, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline providing broad-spectrum activity, and our ability to obtain regulatory approval of omadacycline All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2016, and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.


BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at ASM Microbe 2017, to be held June 1 – 5 in New Orleans. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry. “As we advance our clinical program, we continue to be encouraged by the study outcomes that add to our breadth of knowledge about the safety and efficacy of once-daily oral and IV omadacycline in the treatment of bacterial infections,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer, Paratek. “Results from the 10 studies being presented at ASM Microbe include new phase 1 data examining omadacycline in patients with uncomplicated urinary tract infection as well as additional analyses of microbiology date that help further our understanding of how omadacycline may be used in a clinical setting. We continue to be excited about the potential for this compound to treat severe bacterial infections, particularly when resistance is of concern.” Paratek Presentations on Friday, June 2, 2017 at 12:45 p.m. – 2:45 p.m. CDT (1:45 p.m. – 3:45 p.m. EDT) Poster Session 45: Infection Prevention and Control: Skin, Soft Tissue and Bone Infections Paratek Presentations on Saturday, June 3, 2017 at 12:15 p.m. – 2:15 p.m. CDT (1:15 p.m. – 3:15 p.m. EDT) Poster Session 185: Antibacterial Resistance: In vitro Activity and Resistance to Tigecyline, Fosfomycin and Derivatives Paratek Presentations Sunday, June 4, 2017 at 12:15 p.m. – 2:15 p.m. CDT (1:15 p.m. – 3:15 p.m. EDT) Poster Session 341: Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents Poster Session 345: Clostridium difficile: Epidemiology and Strategies for Prevention and Treatment of CD Infections About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, when approved, will be the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is a new, once-daily oral and intravenous broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for the target indications. In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin structure infections (ABSSSI) demonstrating the efficacy and general safety and tolerability of intravenous (IV) to once-daily oral omadacycline compared to linezolid. In April 2017, Paratek announced positive efficacy data in a Phase 3 registration study in community-acquired bacterial pneumonia (CABP) demonstrating the efficacy and general safety and tolerability of IV to once-daily oral omadacycline compared to moxifloxacin. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. This study completed enrollment in May 2017 and top-line data are expected in mid-July. The Company plans to submit its new drug application (NDA) in the U.S. as early as the first quarter of 2018 with an EMA submission later in 2018. In addition to its Phase 3 program for omadacycline, a Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016 and positive top-line PK proof-of-principle data was reported in November 2016. The Company plans to begin enrolling patients in a proof-of-concept Phase 2 study of omadacycline in acute pyelonephritis, the most common subset of complicated urinary tract infections, as early as December 2017. In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore the utility of omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance including plague and anthrax. In April 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the Company, and Zai Lab (Shanghai) Co., Ltd., entered into a License and Collaboration Agreement. Under the terms of the Agreement, the Company granted Zai an exclusive license to develop, manufacture, and commercialize omadacycline in the People’s Republic of China, Hong Kong, Macau and Taiwan, for all human therapeutic and preventative uses, other than biodefense. Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan and Paratek reported positive results from two identical Phase 3 registration studies of sarecycline for the treatment of moderate to severe acne vulgaris in March 2017. Allergan has publicly announced plans to submit an NDA in the U.S. in the second half of 2017. Forward Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical studies, prospects, potential and expected results, including statements about the timing of advancing omadacycline and otherwise preparing for clinical studies, the timing of enrollment in our clinical studies and our reporting of the results of such studies, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline providing broad-spectrum activity, and our ability to obtain regulatory approval of omadacycline All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2016, and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.


GAITHERSBURG, Md., May 25, 2017 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ:OPGN) today announced that data on its Acuitas® Rapid Test in development and Acuitas Whole Genome Sequence Analysis will be presented at ASM Microbe 2017 being held June 1-5, 2017 in New Orleans, LA. These data will demonstrate the company’s ability to predict phenotypic resistance across antibiotic classes for Gram-negative infections using rapid genetic testing and predictive algorithms from its Acuitas Lighthouse® Knowledgebase. It will also showcase advances in being able to discriminate bacterial strains using more genes to solve current limitations with conventional strain typing methods. The details for the poster presentations at ASM Microbe are as follows: Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance Poster title: Predicting Antibiotic Resistance in Gram-Negative Bacilli by Rapid Detection of Resistance Genes (#87) Presenter: Terry Walker, Ph.D. Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT Location: Exhibit Hall D, Exhibit and Poster Hall Session info: 186 - AAID01 - Antibacterial Resistance: Genomics and New Methodologies to Trace Antimicrobial Resistance Poster title: Core Genome Multilocus Sequence Typing Scheme for High-Resolution Typing of Escherichia coli (#72) Presenter: Weizhong Chang, Ph.D. Date and time: Saturday, June 3, 12:15 – 2:15 PM CEDT Location: Exhibit Hall D, Exhibit and Poster Hall About OpGen OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital and network-wide infection prevention and treatment. Learn more at www.opgen.com and follow OpGen on Twitter and LinkedIn. OpGen®, Acuitas®, Acuitas Lighthouse® and QuickFISH® are registered trademarks of OpGen, Inc.


BOSTON, May 24, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that data from its omadacycline clinical and microbiology programs will be presented at ASM Microbe 2017, to be held June 1 – 5 in New Orleans. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry. “As we advance our clinical program, we continue to be encouraged by the study outcomes that add to our breadth of knowledge about the safety and efficacy of once-daily oral and IV omadacycline in the treatment of bacterial infections,” said Evan Loh, M.D., President, Chief Operating Officer, and Chief Medical Officer, Paratek. “Results from the 10 studies being presented at ASM Microbe include new phase 1 data examining omadacycline in patients with uncomplicated urinary tract infection as well as additional analyses of microbiology date that help further our understanding of how omadacycline may be used in a clinical setting. We continue to be excited about the potential for this compound to treat severe bacterial infections, particularly when resistance is of concern.” Paratek Presentations on Friday, June 2, 2017 at 12:45 p.m. – 2:45 p.m. CDT (1:45 p.m. – 3:45 p.m. EDT) Poster Session 45: Infection Prevention and Control: Skin, Soft Tissue and Bone Infections Paratek Presentations on Saturday, June 3, 2017 at 12:15 p.m. – 2:15 p.m. CDT (1:15 p.m. – 3:15 p.m. EDT) Poster Session 185: Antibacterial Resistance: In vitro Activity and Resistance to Tigecyline, Fosfomycin and Derivatives Paratek Presentations Sunday, June 4, 2017 at 12:15 p.m. – 2:15 p.m. CDT (1:15 p.m. – 3:15 p.m. EDT) Poster Session 341: Antimicrobial Pharmacokinetics: PK/PD of New Antimicrobial Agents Poster Session 345: Clostridium difficile: Epidemiology and Strategies for Prevention and Treatment of CD Infections About Paratek Pharmaceuticals, Inc. Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, when approved, will be the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Omadacycline is a new, once-daily oral and intravenous broad spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians. Omadacycline has been granted Qualified Infectious Disease Product designation and Fast Track status by the U.S. Food and Drug Administration for the target indications. In June 2016, Paratek announced positive efficacy data in a Phase 3 registration study in acute bacterial skin and skin structure infections (ABSSSI) demonstrating the efficacy and general safety and tolerability of intravenous (IV) to once-daily oral omadacycline compared to linezolid. In April 2017, Paratek announced positive efficacy data in a Phase 3 registration study in community-acquired bacterial pneumonia (CABP) demonstrating the efficacy and general safety and tolerability of IV to once-daily oral omadacycline compared to moxifloxacin. A Phase 3 registration study in ABSSSI comparing once-daily oral-only dosing of omadacycline to twice-daily oral-only dosing of linezolid was initiated in August 2016. This study completed enrollment in May 2017 and top-line data are expected in mid-July. The Company plans to submit its new drug application (NDA) in the U.S. as early as the first quarter of 2018 with an EMA submission later in 2018. In addition to its Phase 3 program for omadacycline, a Phase 1B study in uncomplicated urinary tract infections (UTI) was initiated in May 2016 and positive top-line PK proof-of-principle data was reported in November 2016. The Company plans to begin enrolling patients in a proof-of-concept Phase 2 study of omadacycline in acute pyelonephritis, the most common subset of complicated urinary tract infections, as early as December 2017. In October 2016, Paratek announced a research agreement with the U.S. Department of Defense to explore the utility of omadacycline against pathogenic agents causing infectious diseases of public health and biodefense importance including plague and anthrax. In April 2017, Paratek Bermuda Ltd., a wholly-owned subsidiary of the Company, and Zai Lab (Shanghai) Co., Ltd., entered into a License and Collaboration Agreement. Under the terms of the Agreement, the Company granted Zai an exclusive license to develop, manufacture, and commercialize omadacycline in the People’s Republic of China, Hong Kong, Macau and Taiwan, for all human therapeutic and preventative uses, other than biodefense. Paratek's second Phase 3 product candidate, sarecycline, is a well-tolerated, once-daily oral, narrow spectrum tetracycline-derived antibiotic with potent anti-inflammatory properties for the potential treatment of acne and rosacea in the community setting. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Allergan and Paratek reported positive results from two identical Phase 3 registration studies of sarecycline for the treatment of moderate to severe acne vulgaris in March 2017. Allergan has publicly announced plans to submit an NDA in the U.S. in the second half of 2017. Forward Looking Statements This press release contains forward-looking statements including statements related to our overall strategy, product candidates, clinical studies, prospects, potential and expected results, including statements about the timing of advancing omadacycline and otherwise preparing for clinical studies, the timing of enrollment in our clinical studies and our reporting of the results of such studies, the potential for omadacycline to serve as an empiric monotherapy treatment option for patients suffering from ABSSSI, CABP, UTI, and other bacterial infections when resistance is of concern, the prospect of omadacycline providing broad-spectrum activity, and our ability to obtain regulatory approval of omadacycline All statements, other than statements of historical facts, included in this press release are forward-looking statements, and are identified by words such as "advancing," "believe," "expect," "well positioned," "look forward," "anticipated," "continued," and other words and terms of similar meaning. These forward-looking statements are based upon our current expectations and involve substantial risks and uncertainties.  We may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in our forward-looking statements and you should not place undue reliance on these forward-looking statements.  Our actual results and the timing of events could differ materially from those included in such forward-looking statements as a result of these risks and uncertainties.  These and other risk factors are discussed under "Risk Factors" and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2016, and our other filings with the Securities and Exchange Commission.  We expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein.


The present invention relates to a method for manufacturing a shower tray trough, from a composite panel of the sandwich type, to which a mask is applied corresponding to a pattern cavity making it possible to imprint, in the thickness of the foam reinforcing slab of said composite panel, the desired recesses to form said shower tray trough. To that end, the top plate of the composite panel is heated locally, only at the zones corresponding to the recesses to be imprinted, so as to allow the deformation of said top plate and the arrangement of said recesses in the thickness of the foam slab.


-- Assistant Service Manager Michael McKinley of Sun Toyota was recently honored as a 2016 PRO ASM at a recognition banquet held in Hollywood, Florida. Ray Natour, vice president of fixed operations for Toyota's Southeast Region presented McKinley with the award. The Toyota PRO ASM award honors top assistant service managers throughout the Carolinas, Georgia, and Florida for outstanding performance in customer retention, certification, sales, tenure, and customer satisfaction."This is a tremendous honor for Michael and we're exceptionally proud of all his contributions to customer satisfaction and retention all year long," said Managing Partner John Marazzi. "It's quite a feat to earn top honors from among approximately 1,500 Toyota service advisors in Toyota's Southeast Region."Morgan Auto Group acquired Sun Toyota & Scion in February 2016. John Marazzi is the managing partner of Morgan Auto Group's Sun Toyota and Brandon Honda dealerships.The hallmark of a Morgan Auto Group dealership is its keen focus on impeccable customer service and engagement. Sun Toyota is located at 3001 US Highway 19 just south of SR 54 in Holiday, FL 34691 on the border with New Port Richey. For more information, call 727.310.3070 or visit http://www.suntoyota.com/


News Article | May 10, 2017
Site: www.eurekalert.org

Washington, DC - May 9, 2017 - A study published this week in mBio demonstrates that a novel technique can be used to build better vaccines for infectious diseases. The study shows that a practical method, bacterial enzymatic combinatorial chemistry (BECC), can be used to generate functionally diverse molecules that can potentially be used as adjuvants. Vaccines often combine a well-characterized recombinant protein antigen with an adjuvant to increase the immunogenic response of the vaccine. The study is important given the urgent need for new and more effective vaccines against infectious diseases worldwide. "We have identified many promising compounds that could potentially serve as adjuvants for vaccines," said lead author Robert Ernst, PhD, professor in the Department of Microbial Pathogenesis in the School of Dentistry and an adjunct professor in the School of Medicine, at the University of Maryland, Baltimore. To date, vaccine adjuvants have been developed using an empirical trial-and-error approach. Aluminin gels and salts have been used since the 1930's, and monophosphoryl lipid A (MPLA), a modified glycolipid from the outer membrane of a bacterium, has been used since 2009. The envelope of gram-negative bacteria is composed of two distinct lipid membranes, with the outer consisting predominantly of lipopolysaccharides (LPS), of which lipid A is a key component. Lipid A is the anchor that holds the LPS molecule in the bacterial membrane. Roughly fifteen years ago, scientists learned that lipid A is recognized by the toll-like receptor 4 (TLR4), which is instrumental in determining an individual's immune response. The idea for the new study grew out of the fact that scientists have known that some bacteria make specific structures of lipid A that are very pro-inflammatory. The body recognizes them easily, quickly, and at very low amounts. Work in Dr. Ernst's lab, however, showed that many other bacteria had lipid A molecules that were not immunostimulatory. The researchers used the normal bacterial LPS biosynthesis pathway in gram-negative bacteria to synthesize unique lipid A structures based on the presence or absence of specific phosphate, acyl, and carbohydrate groups from a variety of species, to generate novel, rationally-designed lipid A molecules. "Bacteria are very good at what they do. Their enzymes are very specific for which modification can be synthesized, so we engineered bacterial strains that produced the molecules we wanted," said Dr. Ernst. The researchers applied BECC within an avirulent strain of Yersinia pestis to develop structurally distinct LPS molecules and then screened them for their ability to induce pro-inflammatory responses. Lead candidates demonstrated minimal immunostimulation in mouse splenocytes, human primary blood, mononuclear cells, and human monocyte-derived dendritic cells. "We have narrowed down our list of 50 to 70 molecules down to approximately six that have potential adjuvant activity," said Dr. Ernst. He said the system has the potential to generate a diverse array of potential vaccine adjuvants. mBio is an open-access journal of the American Society for Microbiology. The American Society for Microbiology is the largest single life science society, composed of over 50,000 scientists and health professionals. ASM's mission is to promote and advance the microbial sciences. ASM advances the microbial sciences through conferences, publications, certifications and educational opportunities. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to diverse audiences.

Loading ASM collaborators
Loading ASM collaborators